Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926208 | 0.85 | TDP1 (0.45) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL2780755 | 0.85 | TDP1 (0.61) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL30315798 | 0.85 | TSHR (0.59) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL3158500 | 0.85 | TSHR (0.59) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL31670541 | 0.83 | CA1 (0.63) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL329732 | 0.83 | CA1 (0.63) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL2198935 | 0.83 | SMN1; SMN2 (0.46) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL1495405 | 0.83 | KMT2A (0.62) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| Hydrochloric Acid SCHEMBL7951765 | 0.81 | CA1 (0.61) | TDP1KMT2ASMN1; SMN2TSHRPOLB | |
| SCHEMBL27878675 | 0.81 | CA1 (0.61) | TDP1KMT2ASMN1; SMN2TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724641-B | Mildew-proof antibacterial autoclaved aerated block and preparation method thereof | 广州市贤达建材有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-115677544-A | Preparation method of bumetanide | 中科苏州药物研究院 | 2023-02-03 | — | — | CN | claimed |
| CN-104672114-A | A preparing method of 2,4-dichloro-5-sulfamoylbenzoic acid | MEN XIUXIN | 2015-06-03 | — | — | CN | claimed |
| JP-3056440-A | — | — | None | — | — | JP | disclosed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2025215115-A1 | COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES | B&A ONCOMEDICAL (FR) | 2025-10-16 | — | — | WO | disclosed |
| EP-4601744-A1 | NEW COMPOUNDS, PROCESSES FOR PREPARING THE SAME AND THEIR USE AS DRUGS | B&A Oncomedical (FR) | 2025-08-20 | — | — | EP | disclosed |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | ENANTA PHARM INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12054493-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| EP-0127124-A2 | Compounds for treating hypertension | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4377521-A | ANTILIPEMIC | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| EP-0068407-A1 | Aminosulfonylbenzoic acid derivatives | HODOGAYA CHEMICAL CO., LTD. (JP) | 1983-01-05 | — | — | EP | disclosed |
| US-4138399-A | Sulfamylbenzoic acid | PFIZER INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4124590-A | CARDIOVASCULAR DISORDERS, ANTILIPEMIC AGENTS | PFIZER INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3992441-A | ANTILIPEMIC | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3953476-A | DIURETICS | MERCK & CO., INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054493-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TDP1 3722/4885KMT2A 3350/4885SMN1; SMN2 4765/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TDP1 3722/4885KMT2A 3350/4885SMN1; SMN2 4765/4885 |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | HAVCR2, PYGL, SLC10A1 | TDP1 3722/4885KMT2A 3350/4885SMN1; SMN2 4765/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TDP1 3722/4885KMT2A 3350/4885SMN1; SMN2 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.